TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT05066217: Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Clemizole HCl as Adjunctive Therapy in Patients With Lennox-Gastaut Syndrome

Sponsor: Epygenix · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 260 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$565,728

Rescue Site Savings

+$377,152

Unlock Full NCT05066217 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05066217 Rescue Dossier →